Paul Dykes, MD
Nephrology · Brookhaven, MSNPI 1861474827
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.8% of the total across 208 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by AstraZeneca at 24.3% of the total.
Across 208 payments — averaging $19.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Bayer$452
- OPKO Pharmaceuticals, LLC$383
- Aurinia Pharma U.S., Inc.$304
- Akebia Therapeutics Inc$268
- Fresenius USA Marketing, Inc.$253
- plus $1K from 22 others
Across 182 payments — averaging $1869.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Akebia Therapeutics Inc$200K
- OPKO Pharmaceuticals, LLC$113K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$25K
- AbbVie$2K
What the payments were for
- Food & beverage$4,01397%
- Education$1313%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 43 | $1,007 |
| Bayer | 25 | $452 |
| OPKO Pharmaceuticals, LLC | 23 | $383 |
| Aurinia Pharma U.S., Inc. | 14 | $304 |
| Akebia Therapeutics Inc | 16 | $268 |
| Fresenius USA Marketing, Inc. | 12 | $253 |
| Vifor Pharma, Inc. | 12 | $192 |
| Calliditas Therapeutics US Inc. | 9 | $173 |
| Novartis | 6 | $172 |
| ANI Pharmaceuticals, Inc. | 8 | $152 |
| Amgen | 7 | $147 |
| Mallinckrodt Hospital Products Inc. | 5 | $87 |
| Ardelyx, Inc. | 3 | $79 |
| Sunovion Pharmaceuticals Inc. | 3 | $66 |
| Otsuka America Pharmaceutical, Inc. | 2 | $54 |
| Travere Therapeutics, Inc. | 2 | $50 |
| Boehringer Ingelheim | 3 | $45 |
| GSK | 2 | $40 |
| Mallinckrodt Enterprises LLC | 2 | $37 |
| Merck | 2 | $32 |
| Johnson & Johnson | 2 | $31 |
| Scpharmaceuticals Inc. | 1 | $25 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $18 |
| Shield Therapeutics Inc | 1 | $18 |
| Novo Nordisk | 1 | $17 |
| Kyowa Kirin, Inc. | 1 | $15 |
| Lilly USA, LLC | 1 | $14 |
| Daiichi Sankyo Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LOKELMA$252
How this compares
$4,144 in reported general payments places this provider in the 75th percentile of 105 nephrology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 123 | $77,993 |
| VelphoroSucroferric Oxyhydroxide | 51 | $73,385 |
| XphozahTenapanor Hcl | 18 | $55,708 |
| AuryxiaFerric Citrate | 42 | $51,824 |
| EliquisApixaban | 153 | $48,449 |
| AptiomEslicarbazepine Acetate | 61 | $33,143 |
| RayaldeeCalcifediol | 24 | $30,191 |
| EntrestoSacubitril/Valsartan | 111 | $22,709 |
| JardianceEmpagliflozin | 102 | $22,575 |
| XareltoRivaroxaban | 45 | $20,181 |
| KerendiaFinerenone | 31 | $19,400 |
| OzempicSemaglutide | 19 | $18,345 |
| LokelmaSodium Zirconium Cyclosilicate | 26 | $17,266 |
| RenvelaSevelamer Carbonate | 27 | $15,313 |
| VeltassaPatiromer Calcium Sorbitex | 15 | $14,966 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma, Brilinta | $1,007 | $100,029170 claims |
| Fresenius USA Marketing, Inc.Velphoro | $253 | $73,38551 claims |
| Akebia Therapeutics IncAuryxia | $268 | $51,82442 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $66 | $33,14361 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $383 | $30,19124 claims |
| NovartisEntresto | $172 | $22,709111 claims |
| Boehringer IngelheimJardiance | $45 | $22,575102 claims |
| Johnson & JohnsonXarelto | $31 | $20,18145 claims |
| Novo NordiskOzempic, Levemir | $17 | $19,77531 claims |
| BayerKerendia | $452 | $19,40031 claims |
| MerckJanuvia | $32 | $13,29963 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 105 nephrology providers in Mississippi.
Other nephrology in Brookhaven
- Richard MillerBrookhaven$10K
- Mohit AhujaFlowood$427K
- Padam HirachanNatchez$29K
- Brian RifkinHattiesburg$23K
- Otis GowdyMeridian$12K
- Thomas WooldridgeTupelo$8K
- Steven WagnerFlowood$6K
- John Martin LeeTupelo$6K
- Francis PhillippiFlowood$6K
- Son LamOxford$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.